BMRN BioMarin Pharmaceutical Inc. - Common Stock
حول BioMarin Pharmaceutical Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
اقرأ المزيد
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
BMRN لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
BMRN مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
BMRN توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
- شراء قوي 10 30,3%
- شراء 16 48,5%
- احتفاظ 7 21,2%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
26 محللين · 2026-08-21سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $0.73 | $0.70 | 0.03% |
| 31 مارس، 2026 | $0.54 | $0.77 | -0.23% |
| 31 ديسمبر، 2025 | $-0.24 | $0.64 | -0.88% |
| 30 سبتمبر، 2025 | $-0.16 | $0.38 | -0.54% |
| 30 يونيو، 2025 | $1.23 | $0.85 | 0.38% |
| 31 مارس، 2025 | $0.95 | $0.72 | 0.23% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
الميزانية العمومية 28
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
التدفق النقدي 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
السيولة والملاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
معدلات النمو 9
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
قائمة الدخل 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | -383,119,000 | 192,032,000 | 191,907,000 | 190,967,000 | -379,382,000 | 190,429,000 | 190,114,000 | 188,866,000 | -375,000,000 | 188,219,000 | 187,948,000 | 186,667,000 | -369,575,000 | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | -388,203,000 | 192,032,000 | 197,091,000 | 196,474,000 | -400,206,000 | 197,147,000 | 200,505,000 | 199,262,000 | -388,939,000 | 191,173,000 | 194,998,000 | 194,363,000 | -378,968,000 | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | $-2M |
الميزانية العمومية 25
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
التدفق النقدي 13
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | -0.48% | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | -1.3% | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | -0.38% | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | -0.48% | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | -0.11% | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | -0.15% | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | -0.18% |
السيولة والملاءة 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | 5.1 | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | 2.3 | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | -0.5 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | 1.3 |
التقييم (آخر 12 شهرًا) 13
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.36B | $3.11B | · | $3.09B | $3.03B | $2.85B | · | $2.69B | $2.54B | $2.42B | · | $2.28B | $2.23B | $2.15B | · | $1.97B | |
| Net Income TTM | $360M | $501M | · | $502M | $639M | $488M | · | $342M | $292M | $236M | · | $141M | $128M | $193M | · | $105M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | $15.75B | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 31.1 | 22.1 | · | 21.1 | 16.8 | 28.2 | · | 39.7 | 54.5 | 71.0 | · | 121.2 | 129.4 | 96.3 | · | 157.0 | |
| P/S | 3.3 | 3.5 | · | 3.4 | 3.5 | 4.8 | · | 5.0 | 6.2 | 6.8 | · | 7.3 | 7.3 | 8.5 | · | 8.0 | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | 3.4 | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| P / FCF | · | 54.7 | · | · | · | 86.0 | · | · | · | 794.3 | · | · | · | -185.4 | · | · | |
| EV / EBITDA | 129.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.2% | 4.5% | · | 4.8% | 6.0% | 3.5% | · | 2.5% | 1.8% | 1.4% | · | 0.83% | 0.77% | 1.0% | · | 0.64% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| هامش الربح التشغيلي % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| صافي الدخل | $349M | $427M | $168M | $142M | $-64M |
| EPS المخفف | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| النسبة السريعة | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $725M | $487M | $63M | $55M | $209M |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
- Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
- هل BioMarin Pharmaceutical Inc. (BMRN) واحدة من أفضل الأسهم الرخيصة للشراء مع أكبر إمكانات صعودية؟
- عينت شركة BioMarin إيان كلارك رئيسًا لمجلس الإدارة
- تعلن شركة BioMarin Pharmaceutical (BMRN) عن نتائج إيجابية من التجارب الجارية لعقار VOXZOGO
إشارات التداول إشارات شراء/بيع حديثة مع سعر الدخول ونسبة المخاطرة/المكافأة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 616 مقدمي إقرار · $8.6B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 89 (-12 مقابل الربع السابق) | 75 (+10 مقابل الربع السابق) | 195 (-13 مقابل الربع السابق) | 205 (+40 مقابل الربع السابق) | +10.3M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| Dodge & Cox | $849426895 | 14844930 | 9,87% | الأسهم |
| PRIMECAP MANAGEMENT CO/CA/ | $811962329 | 14190183 | 9,44% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $500310680 | 8743633 | 5,82% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494877355 | 8648678 | 5,75% | الأسهم |
| NORGES BANK | $469659128 | 8207954 | 5,46% | الأسهم |
| STATE STREET CORP | $446370874 | 7800959 | 5,19% | الأسهم |
| VIKING GLOBAL INVESTORS LP | $435819735 | 7616563 | 5,07% | الأسهم |
| Vestal Point Capital, LP | $344750500 | 6025000 | 4,01% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $216743752 | 3787902 | 2,52% | الأسهم |
| Capital Research Global Investors | $200521024 | 3504387 | 2,33% | الأسهم |
| FMR LLC | $196878227 | 3440724 | 2,29% | الأسهم |
| Deep Track Capital, LP | $189254063 | 3307481 | 2,20% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $180073856 | 3146120 | 2,09% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $118549312 | 2071816 | 1,38% | الأسهم |
| Assenagon Asset Management S.A. | $100826561 | 1762086 | 1,17% | الأسهم |
| FIRST TRUST ADVISORS LP | $91910897 | 1606273 | 1,07% | الأسهم |
| Jones Hill Capital LP | $81915580 | 1431590 | 0,95% | الأسهم |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76264876 | 1332836 | 0,89% | الأسهم |
| Swedbank AB | $75232112 | 1314787 | 0,87% | الأسهم |
| DNB Asset Management AS | $72566061 | 1268194 | 0,84% | الأسهم |
| Caisse de depot et placement du Quebec | $70749440 | 1236446 | 0,82% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $70030356 | 1223879 | 0,81% | الأسهم |
| AMERIPRISE FINANCIAL INC | $65664916 | 1147544 | 0,76% | الأسهم |
| CITADEL ADVISORS LLC | $64224186 | 1122408 | 0,75% | الأسهم |
| Balyasny Asset Management L.P. | $60344956 | 1054613 | 0,70% | الأسهم |
| ARGA Investment Management, LP | $59474983 | 1039409 | 0,69% | الأسهم |
| GOLDMAN SACHS GROUP INC | $56321074 | 984290 | 0,65% | الأسهم |
| Brandywine Global Investment Management, LLC | $56211687 | 945847 | 0,65% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54484884 | 952200 | 0,63% | عقد خيار الشراء |
| MACKENZIE FINANCIAL CORP | $53321258 | 931864 | 0,62% | الأسهم |
| FRANKLIN RESOURCES INC | $47889936 | 836944 | 0,56% | الأسهم |
| Hudson Bay Capital Management LP | $47206500 | 825000 | 0,55% | الأسهم |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40949264 | 715646 | 0,48% | الأسهم |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39869980 | 696784 | 0,46% | الأسهم |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39311857 | 687030 | 0,46% | الأسهم |
| Palo Alto Investors LP | $39068500 | 682777 | 0,45% | الأسهم |
| Defilade Capital Management, L.P. | $39024326 | 682005 | 0,45% | الأسهم |
| Qube Research & Technologies Ltd | $38270739 | 668835 | 0,44% | الأسهم |
| Eagle Health Investments LP | $35743961 | 624676 | 0,42% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $34419661 | 601532 | 0,40% | الأسهم |
| BOONE CAPITAL MANAGEMENT LLC | $33371791 | 583219 | 0,39% | الأسهم |
| Camber Capital Management LP | $32982000 | 600000 | 0,38% | الأسهم |
| River Road Asset Management, LLC | $31069888 | 542990 | 0,36% | الأسهم |
| RHUMBLINE ADVISERS | $29570438 | 516786 | 0,34% | الأسهم |
| Trails Edge Capital Partners, LP | $29296640 | 512000 | 0,34% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $28048615 | 490189 | 0,33% | الأسهم |
| Jefferies Financial Group Inc. | $26679283 | 466258 | 0,31% | الأسهم |
| LOOMIS SAYLES & CO L P | $25986177 | 454145 | 0,30% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $25856059 | 451871 | 0,30% | الأسهم |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $25588784 | 447200 | 0,30% | الأسهم |
| California Public Employees Retirement System | $25124959 | 439094 | 0,29% | الأسهم |
| Rockefeller Capital Management L.P. | $24797775 | 433376 | 0,29% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24038122 | 420100 | 0,28% | عقد خيار البيع |
| SEB Asset Management AB | $23583178 | 412150 | 0,27% | الأسهم |
| Robeco Institutional Asset Management B.V. | $23358064 | 408215 | 0,27% | الأسهم |
| Pictet Asset Management Holding SA | $22789414 | 395382 | 0,26% | الأسهم |
| BlackRock, Inc. | $22697229 | 396666 | 0,26% | الأسهم |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $22513495 | 393455 | 0,26% | الأسهم |
| PRUDENTIAL FINANCIAL INC | $22325585 | 390171 | 0,26% | الأسهم |
| Soleus Capital Management, L.P. | $21490230 | 375572 | 0,25% | الأسهم |
| Freestone Grove Partners LP | $20839181 | 364194 | 0,24% | الأسهم |
| Sofinnova Investments, Inc. | $20517261 | 358568 | 0,24% | الأسهم |
| Swiss National Bank | $20427540 | 357000 | 0,24% | الأسهم |
| LAZARD ASSET MANAGEMENT LLC | $20049716 | 350397 | 0,23% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $19371831 | 338550 | 0,23% | الأسهم |
| EASTERLY INVESTMENT PARTNERS LLC | $18847524 | 329387 | 0,22% | الأسهم |
| SPHERA FUNDS MANAGEMENT LTD. | $18799631 | 328550 | 0,22% | الأسهم |
| DIADEMA PARTNERS LP | $17901048 | 312846 | 0,21% | الأسهم |
| SECTOR GAMMA AS | $16875208 | 294918 | 0,20% | الأسهم |
| Rhenman & Partners Asset Management AB | $16622410 | 290500 | 0,19% | الأسهم |
| Walleye Capital LLC | $16492692 | 288233 | 0,19% | الأسهم |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $16114296 | 281620 | 0,19% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $16009266 | 283400 | 0,19% | الأسهم |
| Bridgewater Associates, LP | $15730407 | 274911 | 0,18% | الأسهم |
| Susquehanna Portfolio Strategies, LLC | $15653218 | 273562 | 0,18% | الأسهم |
| Redmile Group, LLC | $15172970 | 265169 | 0,18% | الأسهم |
| Amundi | $14864727 | 259782 | 0,17% | الأسهم |
| Eversept Partners, LP | $14282513 | 249607 | 0,17% | الأسهم |
| Distillate Capital Partners LLC | $14242974 | 248916 | 0,17% | الأسهم |
| RICE HALL JAMES & ASSOCIATES, LLC | $14203377 | 248224 | 0,17% | الأسهم |
| CAPITAL FUND MANAGEMENT S.A. | $13470789 | 235421 | 0,16% | الأسهم |
| CITADEL ADVISORS LLC | $13189210 | 230500 | 0,15% | عقد خيار الشراء |
| CANADA PENSION PLAN INVESTMENT BOARD | $12868778 | 224900 | 0,15% | الأسهم |
| M&G PLC | $12317472 | 216096 | 0,14% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12137385 | 214859 | 0,14% | الأسهم |
| GLENMEDE TRUST CO NA | $11782055 | 205908 | 0,14% | الأسهم |
| Retirement Systems of Alabama | $11438907 | 199911 | 0,13% | الأسهم |
| IEQ CAPITAL, LLC | $11328874 | 197988 | 0,13% | الأسهم |
| Mariner, LLC | $11021160 | 192607 | 0,13% | الأسهم |
| Monaco Asset Management SAM | $10582095 | 184937 | 0,12% | الأسهم |
| Engineers Gate Manager LP | $10393841 | 181647 | 0,12% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $9840867 | 171983 | 0,11% | الأسهم |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $9713000 | 169746 | 0,11% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $9595050 | 167687 | 0,11% | الأسهم |
| VAN ECK ASSOCIATES CORP | $9444504 | 165056 | 0,11% | الأسهم |
| PEREGRINE CAPITAL MANAGEMENT LLC | $9310495 | 162714 | 0,11% | الأسهم |
| CWM, LLC | $9018745 | 159652 | 0,10% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9015469 | 157558 | 0,10% | الأسهم |
| BARCLAYS PLC | $8865839 | 154943 | 0,10% | الأسهم |
| Legal & General Group Plc | $8722675 | 152441 | 0,10% | الأسهم |
المطلعون على الشركة 48 من المطلعين · مسؤولون 19 · مديرون 29
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 مارس، 2025 A | 175583 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 2 مايو، 2005 A | 14934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 6 مايو، 2004 P | 79285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 مارس، 2025 A | 99781 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 22 يونيو، 2018 S | 51070 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 مايو، 2012 M | 41089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 سبتمبر، 2024 F | 185074 | 0 | 0 | $0 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 مايو، 2025 F | 30545 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 مايو، 2025 S | 14173 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 17 مارس، 2025 A | 46810 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 مارس، 2025 A | 80838 | 0 | 0 | $0 |
| George Eric Davis | EVP, Chief Legal Officer | 17 مارس، 2025 A | 82915 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 2 مايو، 2024 S | 66767 | 0 | 0 | $0 |
| Robert Baffi | EVP, Technical Operations | 22 يونيو، 2018 M | 83276 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 2 يوليو، 2012 M | 59030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 2 مارس، 2009 M | 39621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 7 يوليو، 2008 A | 12000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 1 ديسمبر، 2005 M | 295176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 أكتوبر، 2004 A | 2740 | 0 | 0 | $0 |
| Elizabeth M Anderson | مدير | 2 يونيو، 2026 A | 41940 | 0 | 0 | $0 |
| Barbara W. Bodem | مدير | 2 يونيو، 2026 A | 21045 | 0 | 0 | $0 |
| Maykin Ho | مدير | 2 يونيو، 2026 A | 35500 | 0 | 0 | $0 |
| Mark J Enyedy | مدير | 2 يونيو، 2026 A | 21040 | 0 | 0 | $0 |
| Athena Countouriotis | مدير | 2 يونيو، 2026 A | 21040 | 0 | 0 | $0 |
| Robert J. Hombach | مدير | 2 يونيو، 2026 A | 49360 | 0 | 0 | $0 |
| Timothy P Walbert | مدير | 2 يونيو، 2026 A | 17270 | 0 | 0 | $0 |
| Ian T Clark | مدير | 2 يونيو، 2026 A | 14490 | 0 | 0 | $0 |
| Willard H Dere | مدير | 2 يونيو، 2026 A | 46440 | 0 | 0 | $0 |
| Richard A Meier | مدير | 20 مايو، 2025 A | 127426 | 0 | 0 | $0 |
| Elaine J Heron | مدير | 3 يونيو، 2024 M | 97720 | 0 | 0 | $0 |
| David E I Pyott | مدير | 21 مايو، 2024 A | 49750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | مدير | 20 مايو، 2024 F | 473792 | 0 | 0 | $0 |
| Dennis Slamon | مدير | 18 مارس، 2024 M | 31299 | 0 | 0 | $0 |
| Mark J Alles | مدير | 23 مايو، 2023 A | 15095 | 0 | 0 | $0 |
| Bryan V Lawlis | مدير | 23 مايو، 2023 A | 33140 | 0 | 0 | $0 |
| Michael G Grey | مدير | 5 يونيو، 2018 A | 34110 | 0 | 0 | $0 |
| Alan Lewis | مدير | 5 يونيو، 2018 A | 25360 | 0 | 0 | $0 |
| Kathryn E Falberg | مدير | 15 يوليو، 2016 A | 2640 | 0 | 0 | $0 |
| William D Young | مدير | 10 يونيو، 2015 A | 11875 | 0 | 0 | $0 |
| Kenneth Bate | مدير | 10 يونيو، 2015 A | 11875 | 0 | 0 | $0 |
| Pierre Lapalme | مدير | 10 يونيو، 2015 A | 31250 | 0 | 0 | $0 |
| Joseph Klein III | مدير | 8 مارس، 2010 S | 35000 | 0 | 0 | $0 |
| Franz L Cristiani | مدير | 14 يونيو، 2006 A | — | 0 | 0 | $0 |
| Erich Sager | مدير | 24 فبراير، 2006 M | 3309 | 0 | 0 | $0 |
| Gwynn Williams | مدير | 30 نوفمبر، 2004 A | 812565 | 0 | 0 | $0 |
| John Urquhart | مدير | 28 يوليو، 2004 A | — | 0 | 0 | $0 |
| BIOMARIN PHARMACEUTICAL INC | مالك 10% | 8 ديسمبر، 2012 J | 6666667 | 0 | 0 | $0 |
| Mark Wood | — | 22 مايو، 2013 M | 20277 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 4 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 إيداعات | 2 فبراير، 2015 | — | إيداع أولي | — | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 إيداعات | 31 يوليو، 2009 | — | إيداع أولي | — | SEC |
| 6 يونيو، 2005 | — | إيداع أولي | حملة مجلس الإدارة | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 إيداعات | 6 مايو، 2005 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 110 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| GNOM · Global X Funds | 4,09% | 39792 NS | 31 مايو، 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2,96% | 171614 SH | 19 أغسطس، 2026 | يومي |
| BBP · ETFis Series Trust I | 1,61% | 17750 NS | 30 إبريل، 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,27% | 12555 NS | 30 إبريل، 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,14% | 40919 NS | 30 إبريل، 2026 | N-PORT |
| RNIN · EA Series Trust | 1,12% | 31743 NS | 30 إبريل، 2026 | N-PORT |
| IBB · iShares Trust | 0,93% | 1413059 SH | 19 أغسطس، 2026 | يومي |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,86% | 10692 SH | 19 أغسطس، 2026 | يومي |
| LABU · Direxion Shares ETF Trust | 0,84% | 80485 NS | 30 إبريل، 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,83% | 133988 NS | 30 إبريل، 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 1977 NS | 30 إبريل، 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 0,64% | 18230 NS | 31 مايو، 2026 | N-PORT |
| BIB · ProShares Trust | 0,55% | 7110 NS | 31 مايو، 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,54% | 3021 NS | 31 مايو، 2026 | N-PORT |
| ABCS · EA Series Trust | 0,48% | 948 NS | 29 مايو، 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,44% | 259 NS | 29 مايو، 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,43% | 24857 NS | 30 إبريل، 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,40% | 26193 SH | 19 أغسطس، 2026 | يومي |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108709 SH | 19 أغسطس، 2026 | يومي |
| PTMC · Pacer Funds Trust | 0,30% | 22042 NS | 30 إبريل، 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2559860 SH | 19 أغسطس، 2026 | يومي |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312378 SH | 19 أغسطس، 2026 | يومي |
| DFSV · Dimensional ETF Trust | 0,29% | 400897 NS | 30 إبريل، 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 31691 NS | 30 إبريل، 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71381 SH | 19 أغسطس، 2026 | يومي |
| ISCV · iShares Trust | 0,27% | 27744 SH | 19 أغسطس، 2026 | يومي |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,25% | 24275 NS | 30 إبريل، 2026 | N-PORT |
| MVV · ProShares Trust | 0,24% | 6639 NS | 31 مايو، 2026 | N-PORT |
| JIII · Janus Detroit Street Trust | 0,22% | 6823 NS | 30 إبريل، 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,21% | 3182 NS | 30 إبريل، 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 77243 NS | 30 إبريل، 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,20% | 518955 NS | 31 مايو، 2026 | N-PORT |
| IYH · iShares Trust | 0,20% | 112848 SH | 19 أغسطس، 2026 | يومي |
| ISCB · iShares Trust | 0,20% | 8655 SH | 19 أغسطس، 2026 | يومي |
| SMMD · iShares Trust | 0,17% | 97330 SH | 19 أغسطس، 2026 | يومي |
| UMDD · ProShares Trust | 0,17% | 927 NS | 31 مايو، 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19998 SH | 19 أغسطس، 2026 | يومي |
| FHLC · FIDELITY COVINGTON TRUST | 0,16% | 84082 NS | 30 إبريل، 2026 | N-PORT |
| FNDA · SCHWAB STRATEGIC TRUST | 0,16% | 245186 NS | 31 مايو، 2026 | N-PORT |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,16% | 31223 SH | 19 أغسطس، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | 0,15% | 534462 SH | 19 أغسطس، 2026 | يومي |
| ISCG · iShares Trust | 0,14% | 21146 SH | 19 أغسطس، 2026 | يومي |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20990 SH | 19 أغسطس، 2026 | يومي |
| DFAS · Dimensional ETF Trust | 0,14% | 361639 NS | 30 إبريل، 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4433137 SH | 19 أغسطس، 2026 | يومي |
| ESML · iShares Trust | 0,13% | 55442 SH | 19 أغسطس، 2026 | يومي |
| IWS · iShares Trust | 0,12% | 288497 SH | 19 أغسطس، 2026 | يومي |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,12% | 8557 NS | 31 مايو، 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,12% | 2217617 SH | 19 أغسطس، 2026 | يومي |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,11% | 204 NS | 31 مايو، 2026 | N-PORT |